4d future26 Mar 2021 08:53
M&As are very common in this sector, and often seem to be for mind boggling sums. $bns for companies at earlier development stage than 4d. Just think what is on offer here, numerous advanced clinical trials, huge patent library, MicroRX and MicroDX platforms, owned manufacturing facilities, collaborations worth $bns. This is screaming to be snapped up right now at such a massive discount.
If positive data comes from the recent Bavencio (Pfizer /MerckKGaA) collaboration, will we see an offer come in from current share holder Merck? Mrx0518 is the big one here right now, and with continued excellent read outs across multiple cancer types and in combination with different drugs, is it too big a risk for one of the above companies not to snap it up for themselves?
Any thoughts?